Inflammation Blood Markers

Non-specific marker of inflammation. Elevated in infection, injury, or chronic disease.

PED: Training-induced inflammation can elevate CRP. Some AAS may increase systemic inflammation. High-sensitivity CRP (hs-CRP) is more useful for cardiovascular risk assessment -- target <1.0 mg/L for low cardiovascular risk. Rest 48-72h before blood draw for accurate baseline.

Non-specific marker of inflammation that measures how quickly red blood cells settle in a tube. Elevated in infection, autoimmune conditions, and chronic inflammation. Slower to rise and fall than CRP.

PED: Complementary to CRP — ESR rises more slowly but stays elevated longer, making it useful for detecting chronic/ongoing inflammation. AAS-induced polycythemia (high RBC/haematocrit) can actually lower ESR because more packed red cells settle slower. If ESR is elevated despite high haematocrit, it suggests significant inflammation. Not typically a primary monitoring marker for PED users, but useful alongside CRP for a complete inflammatory picture.

Amino acid in the blood. Elevated levels are an independent risk factor for cardiovascular disease, stroke, blood clots, and cognitive decline. Metabolised by B-vitamins (B6, B12, Folate).

PED: An often-overlooked cardiovascular risk marker for PED users. Elevated homocysteine damages blood vessel walls and promotes clotting -- compounding the cardiovascular risk from AAS-worsened lipids and elevated haematocrit. Some AAS may affect homocysteine metabolism. Target <10 umol/L for optimal cardiovascular protection.

NMR-derived composite inflammatory biomarker reflecting glycosylation of acute phase proteins. More stable than CRP with lower intra-individual variability, providing a better measure of chronic systemic inflammation.

PED: Chronic PED use causes sustained low-grade systemic inflammation reflected by GlycA. Unlike CRP which spikes acutely and normalises quickly, GlycA captures chronic inflammatory burden — more relevant for long-term health monitoring in enhanced athletes. AAS-induced hepatic acute phase protein production elevates GlycA. Intense training, joint stress, and chronic muscle damage from heavy lifting contribute. GH may reduce GlycA through anti-inflammatory effects, partially counteracting AAS-driven elevation. GlycA independently predicts cardiovascular events and all-cause mortality.

An autoantibody (usually IgM) directed against the Fc portion of the body's own IgG. It is used mainly as a screening and classification aid for rheumatoid arthritis, but it is far from specific and can be raised in many other conditions.

PED: Rheumatoid Factor has low specificity, so a positive result is not a diagnosis. It is elevated in rheumatoid arthritis but also in other autoimmune diseases (Sjogren's, lupus), chronic infections (hepatitis C, endocarditis), and simply with older age, and a meaningful minority of healthy people carry a low-titre positive with no disease. For an athlete with genuine inflammatory joint pain, morning stiffness, and swelling, RF is worth checking alongside anti-CCP (a more specific test), CRP, and ESR. In isolation, and especially at low titre, it is weak evidence and should not trigger alarm. Heavy training soreness and mechanical joint pain are not causes of a raised RF.

An antibody directed against citrullinated proteins that is highly specific for rheumatoid arthritis and often appears years before symptoms. Positivity supports the diagnosis and predicts a more erosive disease course.

PED: Anti-CCP is not affected by AAS, GH, or peptides, but it is worth understanding for lifters. Enhanced athletes frequently have aches, joint pain, and stiffness from heavy training, prior injuries, and osteoarthritis, and it is easy to dismiss genuine inflammatory arthritis as normal gym wear and tear. A positive anti-CCP points to rheumatoid arthritis rather than mechanical joint pain and warrants rheumatology review. Units and cutoffs are strongly assay-dependent, so always read the result against the reporting laboratory's own reference interval. The bodybuilder range equals the standard range.

An autoantibody against double-stranded DNA that is highly specific for systemic lupus erythematosus (SLE). Rising titres often track disease activity, particularly lupus nephritis.

PED: Anti-dsDNA is not affected by AAS, GH, or peptides. It is relevant to enhanced athletes mainly as a confounder: fatigue, joint pain, rashes, and abnormal routine bloodwork can be blamed on cycles or training when an underlying autoimmune disease is present. Anti-dsDNA helps confirm SLE and, because titres can mirror disease activity, is used to monitor flares. Assays and cutoffs vary (ELISA, Farr, immunofluorescence), so interpret against the reporting laboratory's reference interval. The bodybuilder range equals the standard range.

An antiphospholipid antibody targeting beta-2 glycoprotein I. It is one of the laboratory criteria for antiphospholipid syndrome, an autoimmune clotting disorder that causes venous and arterial thrombosis and pregnancy loss.

PED: Anti-B2 glycoprotein I is not affected by AAS, GH, or peptides, but the condition it flags, antiphospholipid syndrome, is directly relevant to enhanced athletes because it compounds thrombotic risk. AAS already raise clot risk through erythrocytosis (high haematocrit) and a prothrombotic haemostatic shift; a positive antiphospholipid antibody adds an independent, powerful clotting drive. Anyone with an unexplained clot, especially a younger lifter, should be evaluated for antiphospholipid syndrome. Criteria require persistent positivity confirmed on repeat testing at least 12 weeks apart. Interpret against the laboratory's own cutoff. The bodybuilder range equals the standard range.

An antiphospholipid antibody directed against cardiolipin. Together with anti-B2 glycoprotein I and lupus anticoagulant, it forms the laboratory criteria for antiphospholipid syndrome, a cause of thrombosis and pregnancy loss.

PED: Anticardiolipin IgG is not affected by AAS, GH, or peptides, but the antiphospholipid syndrome it helps diagnose adds a strong, independent clotting drive on top of the thrombotic risk androgens already create through erythrocytosis and prothrombotic haemostatic changes. Moderate-to-high titre IgG carries more weight than low-level positivity. Criteria require persistent positivity confirmed at least 12 weeks apart, since transient positives occur with infections. Interpret against the laboratory's own cutoff. The bodybuilder range equals the standard range.

The IgM class of anticardiolipin antibody, part of the antiphospholipid antibody panel used in the diagnosis of antiphospholipid syndrome. IgM positivity is less specific than IgG and more often transient.

PED: Anticardiolipin IgM is not affected by AAS, GH, or peptides. Like the IgG class it flags antiphospholipid syndrome, a clotting disorder that compounds the thrombotic risk androgens create through erythrocytosis and prothrombotic haemostatic changes. IgM is more prone to transient positivity (infections, other conditions) and is generally considered less specific than IgG, so persistence and correlation with clinical events matter. Confirm on repeat testing at least 12 weeks apart and interpret against the laboratory's own cutoff. The bodybuilder range equals the standard range.

A central protein of the complement system, part of innate immunity. Levels fall when complement is consumed by immune-complex disease (notably active lupus) and rise as a non-specific acute-phase reactant.

PED: Complement C3 is not affected by AAS, GH, or peptides. It matters for enhanced athletes mostly as part of an autoimmune work-up: a low C3, especially with a low C4 and positive anti-dsDNA, points to active systemic lupus, which can masquerade as training fatigue, joint pain, or unexplained abnormal bloodwork. As an acute-phase protein, C3 can also rise modestly with inflammation, infection, or heavy training, so a high value is far less specific than a low one. The clinically important direction is LOW (consumption). The bodybuilder range equals the standard range.

A protein of the classical complement pathway. Like C3 it is consumed in active immune-complex disease (especially lupus) and can rise modestly as an acute-phase reactant, but C4 often falls earlier and further than C3 in lupus flares.

PED: Complement C4 is not affected by AAS, GH, or peptides. It is used alongside C3 in autoimmune assessment: a low C4, particularly with a low C3 and positive anti-dsDNA, indicates active systemic lupus, which can be mistaken for the fatigue and joint pain of hard training. C4 is often the more sensitive of the two in lupus, sometimes dropping before C3. It can rise mildly as an acute-phase protein, so a high value is non-specific. The clinically important direction is LOW (consumption). The bodybuilder range equals the standard range.

A neutrophil-derived protein measured in stool that reflects inflammation of the gut lining. It is used to distinguish inflammatory bowel disease (Crohn's, ulcerative colitis) from non-inflammatory conditions such as irritable bowel syndrome, and to monitor disease activity.

PED: Faecal calprotectin is not affected by AAS, GH, or peptides directly, but gut symptoms are common in enhanced athletes and this test helps separate serious inflammation from benign causes. High-dose NSAID use for training aches can inflame the gut and raise calprotectin, and very high protein intakes, aggressive cutting diets, and some supplements can provoke GI symptoms. A normal calprotectin makes inflammatory bowel disease unlikely and points toward irritable bowel syndrome; a high result warrants proper gastroenterology work-up rather than self-treatment. The bodybuilder range equals the standard range.

An antibody against gliadin, a component of gluten, historically used to screen for coeliac disease. This is the older native (non-deamidated) gliadin assay, which is less sensitive and specific than deamidated gliadin peptide (DGP) IgG and tissue transglutaminase (tTG) IgA, now the preferred coeliac tests.

PED: Gliadin IgG is not affected by AAS, GH, or peptides. It is relevant to athletes because undiagnosed coeliac disease and gluten sensitivity can cause fatigue, poor recovery, bloating, and malabsorption of iron and other nutrients that then show up on routine bloodwork. Note that this older native gliadin antibody test has largely been superseded: current coeliac screening relies on tissue transglutaminase (tTG) IgA and deamidated gliadin peptide (DGP) IgG, and diagnosis requires the patient to be eating gluten at the time of testing. Treat a positive native gliadin IgG as a prompt for proper coeliac testing, not as a diagnosis. The bodybuilder range equals the standard range.